ARIEL3 Phase 3 trial

December 4, 2019

Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer

News

The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, ... Read more

October 18, 2019December 4, 2019

NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer

News

The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ... Read more

September 27, 2019

Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows

News

Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of ... Read more

June 12, 2019

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

News

Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those subsequent ... Read more

May 24, 2019

After Considering Patients’ Well-being, Rubraca Continues to Benefit Women with Recurrent Ovarian Cancer, Analysis Shows

News

Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients’ perceptions about their health, disease symptoms, and treatment toxicity, a retrospective analysis of ... Read more

January 30, 2019

Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer

News

The European Commission has extended Rubraca‘s (rucaparib) approval as a maintenance therapy for women with advanced, relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. This recent ... Read more

March 28, 2018

EU’s CHMP Supports Rubraca’s Approval for Advanced, Recurrent Ovarian Cancer

News

Rubraca (rucaparib) is a step closer to availability in Europe for ovarian cancer patients with relapsed or progressive disease. The E.U.’s Committee for Medicinal Products for Human Use (CHMP) recently ... Read more

December 8, 2017

FDA Grants Rubraca Speedy Review for Use as Ovarian Cancer Maintenance Treatment

News

The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to Clovis Oncology’s application to expand its approval for Rubraca (rucaparib) to include recurrent ovarian cancer maintenance treatment. A decision ... Read more

October 11, 2017December 8, 2017

Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy

News

Clovis Oncology seeks to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in Boulder, ... Read more

June 21, 2017June 21, 2017

Clovis to Apply for Expanded FDA Approval for Rubraca in Ovarian Cancer Patients

News

Clovis Oncology plans to apply to the U.S. Food and Drug Administration (FDA) for expanded approval of Rubraca (rucaparib) as a second-line and later maintenance treatment for all women with ... Read more